Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Bacterial Gastroenteritis

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Impact of Vascularized Lymph Node Transfer in Reducing the Rate of Cellulitis in Breast Cancer-Related Lymphedema.

Plastic and reconstructive surgery·2025

Same author

Reconstructive breast implant-related infections: Prevention, diagnosis, treatment, and pearls of wisdom.

The Journal of infection·2024

Same author

Effect of local prolonged-release incisional doxycycline on surgical site infection prophylaxis in abdominal colorectal surgery: the SHIELD 1 randomized clinical trial.

International journal of surgery (London, England)·2024

Same author

Mitigating Burnout: Transition to a Condensed Workweek for Advanced Practice Providers in Infectious Diseases.

Journal of the advanced practitioner in oncology·2024

Same author

Gastrointestinal Mucormycosis: An Elusive, Unusual, and Severe Opportunistic Mycosis.

Gastroenterology & hepatology·2023

Same author

Tuberculoid Leprosy Masquerading as Erythema Induratum.

HCA healthcare journal of medicine·2023

Search research articles

Related Experiment Video

Updated: May 30, 2026

Detection and Genogrouping of Noroviruses from Children's Stools By Taqman One-step RT-PCR

Detection and Genogrouping of Noroviruses from Children's Stools By Taqman One-step RT-PCR

Published on: July 22, 2012

Norovirus gastroenteritis successfully treated with nitazoxanide.

Danish M Siddiq¹, Hoonmo L Koo, Javier A Adachi

¹Department of Medicine, Division of Infectious Disease, Baylor College of Medicine, United States.

The Journal of Infection

|August 16, 2011

Summary

This summary is machine-generated.

Norovirus acute gastroenteritis in immunosuppressed patients can be severe. Nitazoxanide effectively treated a patient with refractory leukemia and graft-versus-host disease when immunosuppression reduction was not possible.

More Related Videos

Reverse Genetics Mediated Recovery of Infectious Murine Norovirus

Reverse Genetics Mediated Recovery of Infectious Murine Norovirus

Published on: June 24, 2012

Related Experiment Videos

Last Updated: May 30, 2026

Detection and Genogrouping of Noroviruses from Children's Stools By Taqman One-step RT-PCR

Detection and Genogrouping of Noroviruses from Children's Stools By Taqman One-step RT-PCR

Published on: July 22, 2012

Reverse Genetics Mediated Recovery of Infectious Murine Norovirus

Reverse Genetics Mediated Recovery of Infectious Murine Norovirus

Published on: June 24, 2012

Area of Science:

Gastroenterology
Immunology
Hematology

Background:

Infectious diarrhea frequently affects immunocompromised individuals, posing significant health risks.
Managing infectious diarrhea in patients undergoing intensive treatments like stem cell transplantation is challenging.
Graft-versus-host disease (GVHD) further complicates the immune status of transplant recipients.

Observation:

A 43-year-old patient with relapsed acute myelogenous leukemia, post-hematopoietic stem cell transplantation, and active GVHD presented with severe Norovirus acute gastroenteritis.
The patient experienced large-volume stool output, indicating significant gastrointestinal distress.
Standard therapeutic options, including intravenous immunoglobulin and reduction of immunosuppressive therapy, were deemed unsuitable for this patient.

Findings:

A prompt clinical cure was achieved using nitazoxanide, a broad-spectrum antimicrobial agent.
Nitazoxanide demonstrated efficacy in resolving Norovirus-induced gastroenteritis in a highly complex and immunocompromised patient.
The treatment was successful without the need to reduce the patient's immunosuppressive regimen.

Implications:

Nitazoxanide presents a potential safe and effective therapeutic alternative for infectious diarrhea in severely immunocompromised patients.
This case highlights the utility of nitazoxanide when traditional management strategies, such as altering immunosuppression, are not viable.
Further research into nitazoxanide's role in managing infectious gastroenteritis in complex patient populations is warranted.